Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
Coherus Oncology, Inc. (CHRS) had Pre-Tax Income of $-33.35M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$14.31M |
|
$-20.63M |
|
$4.24M |
|
$10.06M |
|
$46.64M |
|
$-32.33M |
|
$-1.02M |
|
|
Pre-Tax Income |
$-33.35M |
$-33.35M |
|
$-33.35M |
|
$-33.35M |
|
$-20.63M |
|
$-33.35M |
|
$-32.33M |
|
$-31.47M |
|
154.82M |
|
154.82M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$133.79M |
|
$0.86M |
|
$57.40M |
|
$191.18M |
|
$75.51M |
|
$37.25M |
|
$54.84M |
|
$130.34M |
|
$60.84M |
|
$15.85M |
|
$60.84M |
|
154.47M |
|
| Cash Flow Statement Financials | |
$-119.98M |
|
$60.29M |
|
$53.73M |
|
$89.12M |
|
$83.16M |
|
$-5.96M |
|
$4.97M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.77 |
|
-- |
|
-- |
|
0.38 |
|
0.61 |
|
70.35% |
|
-225.98% |
|
-225.98% |
|
-- |
|
-233.08% |
|
-144.20% |
|
$-119.98M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.75 |
|
1.00 |
|
89.66 |
|
-54.81% |
|
-210.40% |
|
-17.44% |
|
-34.00% |
|
$0.39 |
|
$-0.78 |
|
$-0.78 |
|